Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Journal of Medicinal Chemistry|September 6, 2024
Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 ReleaseJoshua M Nicholson, Dexi Yang, Thomas Koelblen, et al.
International Journal of Oncology|September 3, 2010
2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathwaysChien-Ming Li, Ramesh Narayanan, Yan Lu, et al.
Investigative Ophthalmology & Visual Science|June 18, 2010
GTx-822, an ER{beta}-selective agonist, protects retinal pigment epithelium (ARPE-19) from oxidative stress by activating MAPK and PI3-K pathwaysAnand Giddabasappa, Matthew N Bauler, Christina M Barrett, et al.
International Journal of Cancer|August 24, 2012
Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifenJuhyun Kim, Christopher C Coss, Christina M Barrett, et al.
Expert Opinion on Therapeutic Patents|March 23, 2010
Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indicationsMichael L Mohler, Ramesh Narayanan, Christopher C Coss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2023
Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint InhibitorsYizhen Guo, Bryan C Remaily, Justin Thomas, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside EnzalutamideJaimie S Gray, Sajad A Wani, Shahid Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2011
Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134Sheng-Ben Liang, Xiu-Zhi Yang, Young Trieu, et al.
Oncotarget|June 15, 2018
CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128Mohamed Badawi, Jihye Kim, Anees Dauki, et al.
Leukemia & Lymphoma|February 11, 2020
Phase I study of AR-42 and decitabine in acute myeloid leukemiaSophia G Liva, Christopher C Coss, Jiang Wang, et al.
Pageof 7